← Oncology Approval Tracker

FDA DECISION ·

Retevmo

selpercatinib · Eli Lilly

Traditional approvalTraditional conversionTumor-agnostic solid tumors
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults and children age 2 or older with locally advanced or metastatic RET fusion-positive solid tumors confirmed by an FDA-approved test, after progression on or following systemic treatment or when satisfactory alternatives are unavailable.

LAMPGEN ANALYSIS

Why it matters

The traditional approval supports a tumor-agnostic RET fusion indication across age groups. Distinguish the broad label from the specific tumor and pediatric cohorts that informed the decision.

What research teams should watch

Record the RET fusion and assay, prior therapy and age cohort. For rare alterations, referral and tissue access can shape how many patients are identified.

PRIMARY RECORDS

Sources